Best Trending Themes in Biopharmaceuticals Companies in United States
The 102 best Trending Themes in Biopharmaceuticals companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: annexon biosciences.
Wanting to know which Trending Themes in Biopharmaceuticals companies in the United States are pulling the most capital right now? Our directory tracks 102 of them, with $732M in total disclosed funding across the board. Annexon Biosciences leads at $256M, followed by Melinta Therapeutics at $186M and Avidity Biosciences at $143M. No unicorns yet, but the funding concentration at the top is real. According to Verified Market Research, the global biopharmaceuticals market was valued at roughly $162B in 2014 and is projected to reach $278B by 2020, a 9.4% CAGR driven by chronic disease prevalence, an aging population, and accelerating R&D spend.
So what's actually moving the needle this quarter? Biosimilar approvals, viral vector vaccines, and diagnostic biotechnology are the themes drawing the most coverage and investor attention right now. Stringent pharmaceutical regulations keep the bar high, which honestly filters out noise and rewards companies with genuine clinical depth. Investors like Pritzker Group, Safeguard Scientifics, and NewSpring are the ones you'll see backing the active cohort here. The range from Annexon's $256M down to Aniluxx Biotechnology's $200K tells you this market has real stratification, and the companies worth watching are the ones building toward that upper tier fast.
- ResearchAndMarkets.com
Ranked: Best Trending Themes in Biopharmaceuticals companies in United States
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | annexon biosciences Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative… | $256M | 47 mo ago | Public | — | 2011 | DrupalApple iCloud MailPHP+28 | 11 signals Announcements · Regulatory · Earnings | — | — |
| 2 | melinta therapeutics Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to… | $186M | 87 mo ago | Public | — | 2000 | — | 6 signals ▲500% M&A · Contracts | 376 patents Novel boronic acid‑based beta‑lactamase inhibitors for treating resistant bacterial infections | — |
| 3 | avidity biosciences Avidity Biosciences is a biotechnology company that develops oligonucleotide-based therapies for its patients. | $143M | 27 mo ago | Public | — | 2013 | DrupalMariaDBPHP+12 | 8 signals ▼43% M&A · Earnings · Announcements | 369 patents Antibody‑oligonucleotide conjugates for treating muscular dystrophy and related muscle disorders | — |
| 4 | immune design Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases. | $101M | 145 mo ago | Acquired | — | 2008 | — | — | 256 patents Engineered lentiviral/retroviral vectors delivering immunostimulatory genes for cancer therapy | — |
| 5 | Putney High quality and affordable generic pet medicines | $47M | 144 mo ago | Acquired | Jean Hoffman | 2006 | — | — | — | — |
| 6 | Aniluxx Biotechnology Provider of veterinary focused drug research and development services | $200K | 78 mo ago | Seed | Stefan C Weiss Founder & CEO | 2019 | — | — | — | — |
| 7 | acceligen Acceligen is a precision breeding company that addresses long-standing challenges in animal health and… | — | — | Private | — | 2014 | — | — | 6 patents Genetic modification of livestock to produce short-haired animals | — |
| 8 | Actipulse International Medical company specialized in the clinical research and engineering of Non-Invasive Brain technologies for… | — | — | — | — | 2017 | FirebaseChart.jsAstro+10 | — | — | — |
Top 6 Trending Themes in Biopharmaceuticals companies in United States
#1
Public · San Diego, California · founded 2013 · 186 employees$142.5Mraised▾
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
#2
Public · South San Francisco, California · founded 2011 · 77 employees$256Mraised▾
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
#3
Public · New Haven, Connecticut · founded 2000 · 162 employees$186Mraised▾
Developer of novel small-molecule antibiotics intended to focus on the treatment of resistant infections. The company develops treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections and is focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications, enabling clients to get safe and differentiated antibiotics for acute care.
#4
Acquired · Seattle, Washington · founded 2008 · 50 employees$101.1Mraised▾
Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.
#5
Acquired · Portland, Maine · founded 2006 · 60 employees$46.6Mraised▾
Putney is a pharmaceutical company specializing in the development of high quality drugs for pets. We focus on developing generics for frequently used drugs where cost is a barrier to prescribing, compliance or use. Our mission: Partner with veterinary practices to provide high quality medicines that meet pet medical needs and offer cost-effective medicines for pet owners Help vets grow their practices and improve margins by offering the quality, security, speed and cost savings of world class pharmaceutical development and sourcing to the veterinary channel Support veterinary drug choice by providing education to help vets evaluate the best treatment options for their pet patients Our fi
#6
Seed · Raleigh, North Carolina · founded 2019 · 1 employees$200Kraised▾
Developer of novel topical therapeutics designed to cure skin and bone diseases in pets. The company's platform produces novel topical therapeutics that are easy to apply, virtually unnoticeable, and absent the harsh side effects of oral medicines, enabling pet lovers to take care of their pets that suffer from skin diseases.
Funding & investor landscape
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.